Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion type Assertion NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_head.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion description "[Collectively, these experiments support evaluation of lapatinib in combination with pharmacologic mTOR inhibition as a potential strategy for inhibiting growth of HER2-overexpressing breast cancers that show resistance to trastuzumab and poor response to lapatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_provenance.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion evidence source_evidence_literature NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_provenance.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion SIO_000772 22043997 NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_provenance.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion wasDerivedFrom befree-2016 NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_provenance.
- NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_assertion wasGeneratedBy ECO_0000203 NP935306.RAVWJl18WoF5zFibRcFUUix2XRYfLrqVzxcBNAAsYXV2g130_provenance.